Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that its ongoing imaging study evaluating a novel approach to tracking multiple sclerosis has reached its halfway point in patient enrollment, with early results showing a meaningful signal in MS lesions. The study, conducted in collaboration with Massachusetts General Hospital, is evaluating a novel positron emission tomography (PET) imaging tracer that could support the development of Lucid-MS, the company's MS drug candidate.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide. Approximately 2.9 million people are living with the disease globally, and nearly one million of those individuals are in the United States. Most people are diagnosed between the ages of 20 and 40, meaning MS strikes during some of the most productive years of a person's life.
The study is evaluating a technique that allows researchers to tell the difference between nerve damage that may still be reversible and damage that is permanent. This distinction is crucial for developing treatments that can halt or reverse disease progression. The early imaging data showing a promising signal in MS lesions suggests that the tracer may be effective in identifying active disease processes, which could help in monitoring treatment response and guiding therapy decisions.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The company's lead candidate, Lucid-MS, is being developed as a potential treatment for multiple sclerosis. The imaging study is a key component of the development program, as it aims to provide a biomarker for disease activity and treatment efficacy.
The milestone of reaching halfway in patient enrollment is significant as it indicates progress in the clinical development of Lucid-MS. The company expects to complete enrollment and report final results in due course. For more information on the latest news and updates relating to QNTM, visit the company's newsroom at https://nnw.fm/QNTM.
